找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins; Ulf Grawunder,Stefan Barth Book 2017 Springer International Publishing A

[复制链接]
楼主: 使委屈
发表于 2025-3-25 07:15:49 | 显示全部楼层
发表于 2025-3-25 10:55:32 | 显示全部楼层
发表于 2025-3-25 15:19:13 | 显示全部楼层
Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis- disulphide bond in antibodies and antibody fragments. We have demonstrated that the bis-sulphone-derived conjugates retain antigen-binding, are stable in serum and exhibit potent and antigen-selective cell killing in both in vitro and in vivo cancer models. Disulphide re-bridging conjugation is a g
发表于 2025-3-25 19:28:49 | 显示全部楼层
Calicheamicin Antibody-Drug Conjugates for Liquid and Solid Tumor Indications,evelopment, including the ADC, inotuzumab ozogamicin, targeting CD22-positive, liquid tumors including NHL and ALL, and the CD33-targeting gemtuzumab ozogamicin, targeting AML..The recent expansion of the utility of calicheamicin conjugates to solid tumors may have a broader impact on ADC developmen
发表于 2025-3-25 23:59:40 | 显示全部楼层
Enzyme-Based Strategies to Generate Site-Specifically Conjugated Antibody Drug Conjugates,C brentuximab vedotin (Adcetris.) and the anti-HER-2 ADC trastuzumab-emtansine (Kadcyla.), are approved for cancer therapy. In fact, Kadcyla. is only approved as a second-line therapy in breast cancer due to a limited clinical benefit in comparison to standard therapy as a first-line therapy. There
发表于 2025-3-26 00:19:10 | 显示全部楼层
发表于 2025-3-26 05:27:04 | 显示全部楼层
发表于 2025-3-26 11:46:31 | 显示全部楼层
发表于 2025-3-26 16:27:52 | 显示全部楼层
发表于 2025-3-26 19:45:09 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-7 11:32
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表